Spots Global Cancer Trial Database for vaccine
Every month we try and update this database with for vaccine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine | NCT00501137 | Cervical Cancer Genital Warts | HPV (Human Papi... | 9 Years - 26 Years | University of British Columbia | |
| Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma | NCT04460235 | Vaccine Streptococcus P... Acute Myeloid L... Lymphoma, Non-H... | Prevenar13 Pneu... | 18 Years - | Poitiers University Hospital | |
| Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | NCT01416038 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | DPX-Survivac low dose cyclop... | 18 Years - | ImmunoVaccine Technologies, Inc. (IMV Inc.) | |
| Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine | NCT01356823 | Cervical Intrae... Cervical Cancer | 30μg HPV 60μg HPV 90μg HPV Hepatitis B vac... | 18 Years - 25 Years | Xiamen University | |
| Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | NCT02425306 | Melanoma | 6MHP Montanide ISA-5... polyICLC Cyclophosphamid... | 18 Years - | University of Virginia | |
| Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females | NCT02740790 | Human Papilloma... | HPV vaccine Placebo | 9 Years - 45 Years | Shanghai Zerun Biotechnology Co.,Ltd | |
| DC Vaccine for Patients With Ductal Carcinoma In Situ | NCT02061332 | Breast Cancer DCIS | HER-2 Pulsed De... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia | NCT00136422 | Acute Myelogeno... Myelodysplasia | autologous tumo... | 18 Years - | Dana-Farber Cancer Institute | |
| Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers | NCT03568058 | Advanced Cancer | personalized va... Pembrolizumab | 18 Years - | University of California, San Diego | |
| Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | NCT02425306 | Melanoma | 6MHP Montanide ISA-5... polyICLC Cyclophosphamid... | 18 Years - | University of Virginia | |
| DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer | NCT00298298 | Non-Small Cell ... | L-Vax: Autologo... | - | AVAX Technologies | |
| Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer | NCT00078494 | Nasopharyngeal ... | EBV-LMP-2 | - | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors | NCT05359354 | Solid Tumor | Personalized ne... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL | NCT03947775 | Anal Intraepith... Anal Cancer Human Papilloma... | 9-valent HPV va... | 18 Years - | University Health Network, Toronto | |
| Human Papillomavirus Infection and Knowledge and Attitudes About HPV Vaccines Among Men Who Have Sex With Men (MSM) | NCT01300689 | HPV Infection HIV Infection Syphilis | 18 Years - | ChineseAMS | ||
| Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma | NCT03927222 | Glioblastoma | Human CMV pp65-... Temozolomide Tetanus-Diphthe... GM-CSF 111-Indium-labe... | 18 Years - | Duke University | |
| Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma | NCT04460235 | Vaccine Streptococcus P... Acute Myeloid L... Lymphoma, Non-H... | Prevenar13 Pneu... | 18 Years - | Poitiers University Hospital | |
| A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer | NCT00683241 | Ovarian Cancer Peritoneal Canc... | DCVac-L | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation | NCT00428233 | Chronic Lymphoc... | Leukemia cell h... | 18 Years - | Dana-Farber Cancer Institute | |
| MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers | NCT05986981 | Solid Tumor, Ad... | Vaccine | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine | NCT02485964 | Prostate Cancer | Blood draw | 18 Years - | University of Arkansas | |
| Assessing the Immunogenicity of pING-hHER3FL | NCT03832855 | Advanced Cancer | pING-hHER3FL | 18 Years - | Duke University | |
| HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy | NCT02061423 | Breast Cancer | HER-2 pulsed De... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Safety and Immunogenicity of COVID-19 Vaccination in Patients With Cancer | NCT05018078 | Patients With C... COVID-19 Vaccine | Coronavirus vac... | 18 Years - | Beijing 302 Hospital | |
| Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination | NCT00442130 | Chronic Lymphoc... | GM-K562 vaccine stem cell trans... | 18 Years - | Dana-Farber Cancer Institute | |
| Dendritic Cell Vaccine for Head and Neck Cancer | NCT00492947 | Squamous Cell C... | dendritic cell ... | 18 Years - | University of Maryland, Baltimore | |
| Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase | NCT00027144 | Leukemia,Myeloi... Leukemia,Myeloi... | Heat Shock Prot... | 18 Years - | UConn Health | |
| Prostvac in Patients With Biochemically Recurrent Prostate Cancer | NCT02649439 | Prostate Cancer | PROSTVAC -V PROSTVAC-F | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | NCT04267237 | Non-small Cell ... | Atezolizumab RO7198457 | 18 Years - | Hoffmann-La Roche | |
| Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma | NCT03927222 | Glioblastoma | Human CMV pp65-... Temozolomide Tetanus-Diphthe... GM-CSF 111-Indium-labe... | 18 Years - | Duke University | |
| Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma | NCT01456104 | Melanoma | Langerhans-type... | - | Memorial Sloan Kettering Cancer Center | |
| Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females | NCT02740790 | Human Papilloma... | HPV vaccine Placebo | 9 Years - 45 Years | Shanghai Zerun Biotechnology Co.,Ltd | |
| A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age | NCT05496231 | Cervical Intrae... | HPV9 High formu... HPV9 Medium for... HPV9 Low formul... Gardasil 9 | 16 Years - 26 Years | GlaxoSmithKline | |
| Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) | NCT02851056 | Multiple Myelom... | Survivin Vaccin... Autologous Hema... Prevnar 13 Granulocyte-col... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity | NCT00580060 | Melanoma | GM-CSF DNA, NSC... | - | Memorial Sloan Kettering Cancer Center | |
| First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma | NCT04116658 | Glioblastoma, A... | Multiple dose o... | 18 Years - | Enterome | |
| A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | NCT04267237 | Non-small Cell ... | Atezolizumab RO7198457 | 18 Years - | Hoffmann-La Roche | |
| First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma | NCT04116658 | Glioblastoma, A... | Multiple dose o... | 18 Years - | Enterome | |
| PreTeenVax Evaluation | NCT03186430 | Human Papilloma... | Comprehensive V... | 11 Years - 12 Years | Emory University | |
| A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 | NCT04908111 | Non-small Cell ... Esophageal Neop... | ChAdOx1-MAGEA3-... MVA-MAGEA3 Standard of car... MVA-NYESO | 18 Years - | Cancer Research UK | |
| A Vaccine Study for High Risk Cancers | NCT00944580 | Neuroblastoma Rhabdomyosarcom... Osteogenic Sarc... | MAGE-A1, MAGE-A... | 1 Year - 70 Years | Penn State University | |
| PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer | NCT03362060 | Triple Negative... Metastatic Brea... | Pembrolizumab PVX-410 | 18 Years - | Massachusetts General Hospital | |
| Clinical Study of WT2725 in Patients With Advanced Malignancies | NCT01621542 | Cancer | WT2725 | 18 Years - | Sumitomo Pharma America, Inc. | |
| A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011) | NCT01254630 | Herpes Zoster | V212 Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer | NCT01069640 | Non-small Cell ... | HLA-A*0201 or H... | 20 Years - 85 Years | Shiga University | |
| PROvenge Treatment and Early Cancer Treatment | NCT00779402 | Prostate Cancer | Control Sipuleucel-T | 18 Years - 80 Years | Dendreon | |
| Immunochemoradiotherapy in Patients With Pancreatic Cancer | NCT01342224 | Locally Advance... | tadalafil and v... | 18 Years - | Providence Health & Services | |
| Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS) | NCT00840931 | Leukemia | lenalidomide bystander vacci... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide | NCT03495921 | Ewing Sarcoma Ewing Family of... Ewing's Tumor M... Ewing's Sarcoma... Ewing's Tumor R... Rare Diseases Sarcoma Neoplasms, Conn... Neoplasms by Hi... Neoplasms, Bone... Neoplasms, Conn... Sarcoma, Ewing Neoplasms | Vigil Irinotecan Temozolomide | 2 Years - | Gradalis, Inc. | |
| Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer | NCT01420965 | Prostatic Neopl... | CT-011 (Anti-PD... Sipuleucel-T (P... Cyclophosphamid... | 18 Years - | Augusta University | |
| A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | NCT02439450 | Non-small Cell ... | Viagenpumatucel... Nivolumab Pembrolizumab Pemetrexed | 18 Years - | Heat Biologics | |
| Evaluation of Long-term HPV Vaccine Efficacy | NCT01393470 | Uterine Cervica... | Screening for c... | 16 Years - 19 Years | Tampere University | |
| Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free | NCT01141491 | Sarcoma | Trivalent gangl... OPT-821 | 16 Years - | MabVax Therapeutics, Inc. | |
| GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer | NCT00089856 | Prostate Cancer | Immunotherapy w... Chemotherapy (T... | 18 Years - | Cell Genesys | |
| Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor | NCT03590808 | Influenza Solid Carcinoma | Influenza vacci... | 20 Years - | Seoul National University Hospital | |
| Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer | NCT01069640 | Non-small Cell ... | HLA-A*0201 or H... | 20 Years - 85 Years | Shiga University | |
| Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase | NCT00027144 | Leukemia,Myeloi... Leukemia,Myeloi... | Heat Shock Prot... | 18 Years - | UConn Health | |
| A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma | NCT02385669 | Melanoma | Ipilimumab 6MHP | 18 Years - | University of Virginia | |
| Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers | NCT05153304 | Cancer of Gastr... | personalized va... Nivolumab | 18 Years - | University of California, San Diego | |
| Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance | NCT06070961 | Follicular Lymp... | Cellular immuni... Humoral immunit... Cellular immuni... Humoral immunit... Diphtheria toxi... Tetanus toxoid-... T-cell populati... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation | NCT01483274 | Acute Myelogeno... | Vaccine | 18 Years - 75 Years | University of Louisville | |
| Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF | NCT00458536 | Renal Cancer | Dendritic Cell ... Granulocyte Mac... | 18 Years - | Beth Israel Deaconess Medical Center | |
| Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma | NCT00487305 | Follicular Lymp... | Lethally Irradi... | 35 Years - | Dana-Farber Cancer Institute | |
| Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City | NCT02382900 | Human Papilloma... | quadrivalent hu... | 10 Years - 11 Years | Universidad Nacional Autonoma de Mexico | |
| Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older | NCT00741039 | Breast Cancer Lung Cancer Prostate Cancer | inactivated inf... inactivated inf... | 65 Years - | Memorial Sloan Kettering Cancer Center | |
| Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer | NCT00078494 | Nasopharyngeal ... | EBV-LMP-2 | - | National Institutes of Health Clinical Center (CC) | |
| Alternate Dosing Schedules Study for HPV Vaccine (ADS) | NCT02280642 | Cervical Cancer Genital Warts | Both 2nd and 3r... 2nd dose late a... 2nd dose on tim... Both doses late | 9 Years - 18 Years | Duke University | |
| The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata | NCT00941889 | HIV Positive Anal Condylomat... Anal Warts HIV Infections | Saline Quadrivalent Hu... | 18 Years - | Washington University School of Medicine | |
| MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer | NCT04078269 | Non-small Cell ... | Dendritic cell ... Antigen-specifi... Control DTH | 18 Years - | University Hospital, Ghent | |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | NCT01353222 | Urothelial Carc... | DN24-02 Standard of Car... | 18 Years - | Dendreon | |
| The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata | NCT00941889 | HIV Positive Anal Condylomat... Anal Warts HIV Infections | Saline Quadrivalent Hu... | 18 Years - | Washington University School of Medicine | |
| Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer | NCT02648282 | Pancreatic Canc... | Cyclophosphamid... GVAX Pancreatic... Pembrolizumab SBRT | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer | NCT04627246 | Pancreatic Aden... | Autologous Dend... | 18 Years - | Centre Hospitalier Universitaire Vaudois | |
| Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma | NCT04523688 | Glioblastoma Vaccination | Autologous Dend... Temozolomide | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA | NCT02211027 | Head and Neck S... | Semi-allogenic ... | 18 Years - | University of Pittsburgh | |
| Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) | NCT00793208 | Non Small Cell ... | semi-allogeneic... | 18 Years - | University of Pittsburgh | |
| Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma | NCT01883518 | Sarcoma Neoplasms, Conn... | Autologous dend... | 18 Years - | N.N. Petrov National Medical Research Center of Oncology | |
| Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia | NCT00136422 | Acute Myelogeno... Myelodysplasia | autologous tumo... | 18 Years - | Dana-Farber Cancer Institute | |
| Prostvac in Patients With Biochemically Recurrent Prostate Cancer | NCT02649439 | Prostate Cancer | PROSTVAC -V PROSTVAC-F | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors | NCT02444936 | Shingles | ZOSTAVAX | 50 Years - | Louis Stokes VA Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
